Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease
Authors:
- Kunio OhnishiKOKunio Ohnishi
- Shin FukuiSFShin Fukui
- Kazuhiko YamadaKYKazuhiko Yamada
- Makoto YamamuraMYMakoto Yamamura
- Kuniki AmanoKAKuniki Amano
- Kanzo AmanoKAKanzo Amano
- Masaaki WadaMWMasaaki Wada
- Noritoshi TanidaNTNoritoshi Tanida
- Masamichi SatomiMSMasamichi Satomi
- 1 June 1995
- journal article
- clinical trial
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 30 (3) , 322-329
Abstract
Leukocytapheresis (LCAP), performed with a leukocyte removal filter, was administered five times, at 1-week intervals, for 5 weeks of intensive therapy and five times, at approximately 1-month intervals, for approximately 5 months of maintenance therapy, to 13 patients with inflammatory bowel disease (IBD) diagnosed as ulcerative colitis (UC) in 8 and Crohn's disease (CD) in 5. Clinical and blood examinations showed no side effects in any of the patients. During the intensive therapy, excellent or moderate clinical response was recognized in 11 of the 13 patients (84.6%), of whom 6 had a dramatic response; the excellent or moderate clinical response continued throughout the maintenance therapy in 8 of the patients (61.5%). Flow cytometry showed that the patients who had improved generally had high values for percentages of HLADR+, HLADR+CD3+, and HLADR+CD8+ cells before the first LCAP, and that these values and the C-reactive protein levels and erythrocyte sedimentation rates had decreased to the normal range by the end of both intensive and maintenance therapy. In the patients who showed poor response, in contrast, all the above values had been at or near normal before the initial LCAP administration. The clinical improvement in the absence of any additional medical treatment suggests that LCAP has the capacity to influence the causal mechanism(s) of IBD and that IBD is strongly associated with the cell-mediated immune response.Keywords
This publication has 11 references indexed in Scilit:
- Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence ofin vivoactivation in active diseaseClinical and Experimental Immunology, 1991
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 1991
- Pharmacological Studies of FUT-175, Nafamstat Mesilate I. Inhibition of Protease Activity in in Vitro and in Vivo ExperimentsThe Japanese Journal of Pharmacology, 1984
- Leukapheresis in rheumatoid arthritis association of clinical improvement with reversal of anergyArthritis & Rheumatism, 1983
- Crohn's DiseaseScandinavian Journal of Gastroenterology, 1971
- Response to azathioprine in ulcerative colitisDigestive Diseases and Sciences, 1966
- A CRITICAL ANALYSIS OF THE USE OF SALICYLAZOSULFAPYRIDINE IN CHRONIC ULCERATIVE COLITISAnnals of Internal Medicine, 1959
- Cortisone and Corticotrophin in Ulcerative ColitisBMJ, 1959
- Life History of Non-Specific Ulcerative Colitis: Relation of Prognosis to Anatomical and Clinical VarietiesDigestion, 1956
- Cortisone in Ulcerative ColitisBMJ, 1954